Arylsulfatase A Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Arylsulfatase A (ARSA) is a lysosomal hydrolase that catalyzes the desulfation of cerebroside sulfate. Deficiency causes metachromatic leukodystrophy (MLD), a devastating demyelinating disease. This enzyme plays a critical role in maintaining the lipid composition of myelin sheaths throughout the central and peripheral nervous systems.
| Property |
Value |
| Protein Name |
Arylsulfatase A |
| Gene |
ARSA |
| UniProt ID |
P15289 |
| Molecular Weight |
54 kDa (511 amino acids) |
| Subcellular Localization |
Lysosome |
| Protein Family |
Arylsulfatase family |
| Structure |
Homodimer, requires formylglycine cofactor |
| PDB ID |
1NUS, 2V4J |
ARSA requires a unique post-translational modification for catalytic activity:
- Formylglycine (FGly) cofactor: Generated by the formylglycine-generating enzyme (FGE) at a conserved cysteine motif (C/S-X-P-X-R)
- Active site: FGly coordinates sulfate ester hydrolysis
- Homodimer formation: Two ARSA subunits associate for optimal activity
- Glycosylation: N-linked glycans target the enzyme to lysosomes
The crystal structure reveals a compact α/β fold with the active site located in a deep pocket, accessible to substrate cerebroside 3-sulfate.
- Hydrolyzes cerebroside 3-sulfate (sulfatide) to galactocerebroside
- Essential for proper myelin lipid metabolism
- Maintains sulfatide homeostasis in myelin-producing cells
- Supports oligodendrocyte function and survival
- Enables normal myelination during development
- Maintains myelin integrity throughout life
- Regulates lipid raft composition in myelin membranes
ARSA shows specific expression patterns:
- Oligodendrocytes: High expression in myelin-producing cells
- Neurons: Moderate expression throughout the brain
- Peripheral nervous system: Schwann cell expression
- Systemic tissues: Kidney, liver, lung (lower levels)
- Inheritance: Autosomal recessive ARSA mutations
- Pathogenesis: Accumulation of sulfatide in myelin sheaths
- Progressive demyelination: Leading to motor decline and cognitive impairment
- Clinical forms: Late infantile, juvenile, adult onset
- Symptoms: Gait disturbance, weakness, vision loss, cognitive decline
- Altered ARSA expression documented in AD brain tissue
- Dysregulated sulfatide metabolism in AD patients
- Potential interaction with amyloid processing
- Sulfatide depletion may contribute to synaptic dysfunction
- Altered ARSA activity in some MS patients
- Potential role in demyelination pathophysiology
- Research ongoing on enzyme modulation
- ARSA expression changes in PD brain
- Lipid metabolism alterations in PD
- Connection to lysosomal function
- Libmeldy (atidarsagene autotemcel): AAV gene therapy approved in Europe for MLD
- Enzyme replacement therapy: Recombinant ARSA delivery
- Substrate reduction therapy: Reduce sulfatide accumulation
- Pharmacological chaperones: Increase residual ARSA activity
- AAV gene therapy: For CNS and peripheral delivery
- Blood-brain barrier penetration strategies
- Early intervention for pre-symptomatic patients
- Combination therapies targeting multiple pathways
- ARSA knockout mice: Sulfatide accumulation, neurological phenotype
- ARSA-deficient dogs: Large animal model for therapy development
- Zebrafish models: Developmental studies
- iPSC models: Patient-derived neurons for drug screening
- ARSA gene therapy for MLD. Mol Ther. 2020. PMID:32402755
- MLD natural history. Brain. 2018. PMID:29538632
- Cerebroside sulfatide metabolism in AD. J Neurosci Res. 2019. PMID:30536542
- ARSA mutations and phenotype correlation. Hum Mutat. 2017. PMID:28229538
- Enzyme therapy for MLD. Neurology. 2021. PMID:34089012
The study of Arylsulfatase A Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [1] Biffi A, et al. ARSA gene therapy for MLD. Mol Ther. 2020.
- [2] van Rappard DF, et al. MLD natural history. Brain. 2018.
- [3] Eckhardt M, et al. Cerebroside sulfatide metabolism in AD. J Neurosci Res. 2019.
- [4] Gieselmann V, et al. ARSA mutations and phenotype. Hum Mutat. 2017.
- [5] Sevin M, et al. Enzyme therapy for MLD. Neurology. 2021.